<SEC-DOCUMENT>0001193125-12-297713.txt : 20120709
<SEC-HEADER>0001193125-12-297713.hdr.sgml : 20120709
<ACCEPTANCE-DATETIME>20120709171233
ACCESSION NUMBER:		0001193125-12-297713
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120703
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120709
DATE AS OF CHANGE:		20120709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		12953905

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d378953d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): July&nbsp;9, 2012 (July 3, 2012) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>810 Seventh Avenue, 35<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, New York, 10019 </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
489-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NONE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. (the &#147;Company&#148;) has announced the retirement of Robert Ladd as a member of the Company&#146;s Board of Directors (the
&#147;Board&#148;), effective July&nbsp;3, 2012. Mr.&nbsp;Ladd will continue to serve as a consultant to the Company. The Company has also announced that the Board has appointed Laura Brege as a Class I Director of the Company to fill the vacancy
created by Mr.&nbsp;Ladd&#146;s resignation, effective as of July&nbsp;5, 2012. The Board also voted to increase the size of the Board from seven to eight directors, and appointed Tasos Konidaris as a Class I Director to fill the vacancy created by
the increase in Board size, effective as of July&nbsp;5, 2012. Mr.&nbsp;Konidaris and Ms.&nbsp;Brege&#146;s Class I terms will each expire at the Company&#146;s annual meeting of stockholders in 2013. Mr.&nbsp;Konidaris has been assigned to the
Audit Committee of the Board, conditioned upon the Board receiving his completed NASDAQ Independence Questionnaire and making a determination that he is independent and a financial expert, and Ms.&nbsp;Brege has been assigned to the Compensation
Committee of the Board, conditioned upon the Board receiving her completed NASDAQ Independence Questionnaire and making a determination that she is independent. Ms.&nbsp;Brege and Mr.&nbsp;Konidaris will each receive standard director fees and
benefits, including a grant of stock options under the Company&#146;s 2009 Stock Incentive Plan (the &#147;Plan&#148;). The number of options to be granted was determined using an option pricing model, so that $75,000 worth of options were awarded
to each new director, vesting over three years, at an exercise price per share equal to the Fair Market Value thereof on their effective dates, as determined in accordance with the Plan. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;9, 2012, the Company issued a press release announcing the changes in Board composition, a copy of which release is filed as Exhibit 99.1 to
this Form 8-K. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item 9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following exhibit is filed herewith: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated July 9, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: July&nbsp;9, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Executive Vice President, General Counsel</FONT></TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated July 9, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d378953dex991.htm
<DESCRIPTION>PRESS RELEASE OF DELCATH SYSTEMS, INC.
<TEXT>
<HTML><HEAD>
<TITLE>Press Release of Delcath Systems, Inc.</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g378953g06f48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DELCATH ANNOUNCED CHANGES TO BOARD OF DIRECTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pharma Industry Veterans Laura A. Brege and Tasos G. Konidaris Join Delcath Board; Robert Ladd to Retire </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, NY &#150; July&nbsp;9, 2012 &#150; Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on
oncology, announced today the appointment of pharmaceutical industry veterans Laura A. Brege and Tasos G. Konidaris to the Company&#146;s expanded Board of Directors, and the retirement of Robert B. Ladd, member of the Company&#146;s Board of
Directors since 2006. Mr.&nbsp;Ladd&#146;s resignation became effective as of July&nbsp;3, 2012, and the appointment of the new directors became effective as of July&nbsp;5, 2012. The changes increase the size of the Board of Directors from seven to
eight. Both Ms.&nbsp;Brege and Mr.&nbsp;Konidaris will serve as Class I directors with terms expiring at the 2013 annual stockholder meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Brege brings more than 30 years of experience in biotechnology and venture capital sectors to the Board. She has successfully led the strategic
expansion of companies and been part of developing and implementing the worldwide commercial strategy to prepare for the launch of a new drug. Mr.&nbsp;Konidaris has more than 20 years of finance and operational experience in the global
pharmaceutical, medical technology and business information industries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Laura Brege and Tasos Konidaris possess
significant financial and health care backgrounds, making them strong additions to our board,&#148; said Dr.&nbsp;Harold&nbsp;S. Koplewicz, Chairman of Delcath&#146;s Board of Directors. &#147;Their experience with global product launches and
partnership development together with their track record of increasing shareholder value will be invaluable assets to us as we continue to expand our commercialization efforts for our Hepatic
CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Delivery System globally.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Robert Ladd was an early champion of the potential of chemosaturation therapy, first as a Delcath investor and as a member of the Delcath Board of Directors since 2006. From his position on the Delcath
Board, Mr.&nbsp;Ladd played a pivotal role in attracting pharmaceutical and medical device industry veterans to the Board and management team. In addition to his work with Delcath, Mr.&nbsp;Ladd has had a distinguished career as an investment
manager, and he currently serves as CEO and a director of MGT Capital Investments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We thank Rob Ladd for his many contributions to
Delcath&#148; Dr.&nbsp;Koplewicz added. &#147;Rob&#146;s wise counsel has been critical to the realization of chemosaturation therapy&#146;s potential, and to Delcath&#146;s transition to a fully commercial enterprise.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Laura A. Brege </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Most recently, Ms.&nbsp;Brege served as Executive Vice President of Corporate Affairs at Onyx Pharmaceuticals, a global biopharmaceutical company engaged in the development and commercialization of
innovative therapies for improving the lives of people with cancer. During her six-year tenure at Onyx, Ms.&nbsp;Brege held a number of senior management positions, including Chief Operating Officer during which time she led the U.S. commercial
team. The team launched Nexavar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (sorafenib), an oral drug in two indications, kidney cancer in 2006 and liver
cancer in 2007. Ms.&nbsp;Brege also led the company&#146;s partnership with Bayer AG on the worldwide development and commercialization of Nexavar<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, which delivered global sales of more than $1 billion in 2011, up from $165 million in 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior to joining Onyx, Ms.&nbsp;Brege held a number of positions, including General Partner of Red Rock Management, a venture capital firm, Senior Vice President and Chief Financial Officer of COR
Therapeutics, a biotechnology company focused on cardiovascular disease, CFO of Flextronics, Inc, a global technology company and Treasurer of The Cooper Companies, a diversified medical products company. She currently serves on the boards of Acadia
Pharmaceuticals and Pacira Pharmaceuticals, as well as the Foundation Board of Ohio University. Ms.&nbsp;Brege received her Master&#146;s in Business Administration from the University of Chicago and her undergraduate degrees in Economics and
Political Science from Ohio University, Honors Tutorial College, where she graduated summa cum laude. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tasos G. Konidaris </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, Mr.&nbsp;Konidaris serves as Senior Vice President and Chief Financial Officer at Ikaria Inc., a company focused on bringing therapeutics to
critically ill patients. At the company, Mr.&nbsp;Konidaris leads the finance function, focusing on developing strategies to maximize profitable growth, return of capital to shareholders, and ensuring financial controls and compliance in support of
long-term growth strategy. Prior to joining Ikaria Inc., Mr.&nbsp;Konidaris served in several senior positions at Dun&nbsp;&amp; Bradstreet Corporation (D&amp;B), including Senior Vice President and Chief Financial Officer, and Principal Accounting
Officer. While at D&amp;B, Mr.&nbsp;Konidaris was instrumental in overseeing the finance function of this $1.7 billion global, publically traded corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Previously, Mr.&nbsp;Konidaris held senior positions at a range of companies, including Group Vice President of the Global Pharmaceutical Group at Schering-Plough Corporation; Vice President of Finance
for North America and Global Business Management at Pharmacia Corporation. Prior to his time at Pharmacia, Mr.&nbsp;Konidaris held senior finance management positions at several global pharmaceutical companies including Rhone-Poulenc Rorer, Novartis
Corporation, and Bristol-Myers Squibb. Mr.&nbsp;Konidaris received his Master&#146;s in Business Administration from Drexel University. He received his Bachelor of Science with a dual major in mathematics and finance at Gwynedd Mercy College, where
he graduated with honors. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>About Delcath Systems</U></I></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath&#146;s proprietary system
for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company&#146;s initial focus is on the
treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study&#146;s primary endpoint of extended
hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The
right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its
NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company&#146;s website at www.delcath.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to,
uncertainties relating to: the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers
in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the
chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised
in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company&#146;s NDA by the FDA, approval of the Company&#146;s NDA for the treatment of metastatic melanoma to the
liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for
the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research
and development projects and future clinical trials, acceptance of our IND amendment, the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial
and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Contact:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Media Contact:</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory Gin/Doug Sherk</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Janine McCargo</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EVC Group</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-455-4801/415-896-6818</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-528-4034</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g378953g06f48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g378953g06f48.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0LB17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$R.C`W.C`Y(#`P.C0S
M.C0X``````.@`0`#`````?__``"@`@`$`````0```06@`P`$`````0```$D`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)]`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`+O^-_.RL5_2OLU]M$MR7/%5CJ]T?9MN[TG-5'K7U/Z_
MTCH1ZYC]=RKS2QEMM)?;6YK';=SJK6Y%FYU6_P#=^@G_`,<EH?U+IV/.K<>U
MW^>]C/\`T4A_6+_&`_ZP]+_8/1^G7@Y&QEI(]2PL80_TJ*<;?_.;/?8__!_X
M/_1VX"7!CX0*UX_[ML,B.*5D^#T/U3^O#1]4;^I=>M+[.G6G'=8`#9=+668[
M6L;M:_(?ZOI?];]>W_"/06?XUF5OHNS^CY.)TW*)]'-W!^YK='6-KV5M?L_P
MGI76?]<6-U+ZF]8P/J!6PTNLR_MPS\S'K&]]=9J?B,;^CW>KZ+?3LN]/]^W_
M`$2QL+)^J&=@X>!FV=8NSO;2S$JNK=0+715.,+OYFM^[Z.S?5_-H#'CEQ2`L
M61I^BKBD*'@'=_QB9N5;];>F48>7:RC)Q\:!3:]K'"W(M9O_`$3VM=O9^>NE
M^M/^,7!Z!G?LZK&?G9C0TVL:X5L9O&ZNLV;;'ON>US'^FRK\]<C]9:::/\87
M1>FU$FK"_9N*S=J=K+=S=Q_>V.4>MV7?57_&([K/4,9U^)9<Z^EW`>RROTG>
MB]_Z/U\1S_YI_P#T/4KM1X(D0!%U`R`^7B59'%_>`OL]MTOZ[G-Z'F]5OZ9D
M46X-@J."T&RY[G^GZ7IL<RE_O==_HUEYG^,W/Z<ZIW4_J[DX>/<3L?98`\AO
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M^*SU+WBMO`GD_P!5H]SD'&ZI@93_`$Z;07GAK@6D_P!7>&[ED>I5:#U;.:;1
M8XLPL7F0#'T?]?\`STG(Q,]_V6S%/3\PC=0X#:"1J)]M?A^[_44?`.M^:^WH
M4E2Z3EV9.+%VF10XU7#^4W\[^TKJ811I+__0]*=?DAQ`88!('L[?]N)?:,K_
M`$9_S/\`U*L[J60,?K^$Y]YM9:&5#!KN<RQCG.>&YHQ*GM^W8[_H97KL?]DJ
MQ_M-7_:I&S>HYU'5:^G5-K)RQ6_%<YKC#*WG]JFW:[_`XYQ_LW_=C)_/1OP5
M3;^T97^C/^9_ZE41=D!Q<*B''D^GJ?\`P1!NZC97UZC!-K/1NJ);4P!UGJ#U
M'O.2-WJ44>FQGV:YM?I>KZ]-]E=EF'ZLNGY=UN;U2NRX7#&O:VK'#0U];333
M9#CN]_K6.L?6^Q*_!5)OM&5_HS_F?^I4SKLAPAU1(/(-<_\`HQ4?JYU3.ZDP
MVY#\=S356]]=3YLJN?O];&MJ^E6VKV5_I_3R/69?ZE?^CSOVWUTT?:?5H`.-
M]L%8I?\`Z7T:<;<;O\+5_.V?SE=WZ1GZ+]"E?@JG?]?)B/3,>'I_^I$FW9#1
M#:B`.`*X'_GQ5\WJ-V/UO!P_48*,H/!K:`ZTO`<]KGLW;V8NQC_T[&>R[^=]
MBT:;JKZF74O;;5:T/KL80YKFN&YCV/;[7,<U*_!5-8WY)!!K)!Y!K_\`4B0O
MR0(%9`'`%?\`ZD0LRVT=9Z=2Q[FUO9D/L:#[7;14UF_^JZWVJL.I=2/5_2W5
M'#^VG#;6&.W[?L?V]USKM^W>W(:^O^:]/T?^%2OP53=LR<EM;B6N8`#[A47$
M>>WU#N5-F8;\3('VBRZDL<++33MV`CW;=OIM=[?Y**WJ%K^N683[ZL=M(;Z6
M,YOZ7(#F&Q]];W.;^BK=^B_0L?L?CW^M_.5^G?W49>.X,>+*K`ZLN:01H358
M)'[KMS41(=D4Y%8I%^%M>YSJ:2<:OT]'-(UO^G]+:A7W7W8561:2^RK+:W&N
M<S8Y[9'YD#_6M*BNZVMF(UXIZGTYQ%)=H'L/;_,1GLRQ8S/ZP]K*L8S52S\Y
M_P";I_YG_F*3K_*_I_>0SJL?3U#J0IF)K<2UF^"6>X[6N:IX6=;;O]*Y^4!$
MEU.W;Y;F^DU$Z+59Z%F7<(LS'FV/!O\`@PM%,D19%7M^"0__T?551K^P_M>S
MZ?V[TO;ZGJ;/2EGJ?9/4_5_YST?M?V?W[_L_VG_`+YC224_522^54DE/U4DO
ME5))3]46>GL=ZD;(._=$;?SMT_FI5^GZ;?2CTX&S;&W;'MVQ^:OE=))3]5)+
MY5224_522^54DE/TEUW]G[F>IO\`MFGI^C]..V[^3^[^?_HU0QOL/VIG[2^T
M;OS/M'T/[>[W[?\`P+_2+Y\24T?EZ_R_=6G=^JDE\JI*%<__V?_M#[!0:&]T
M;W-H;W`@,RXP`#A"24T$)0``````$``````````````````````X0DE-`^T`
M`````!``2`````$``0!(`````0`!.$))300F```````.`````````````#^`
M```X0DE-!`T```````0````>.$))3009```````$````'CA"24T#\P``````
M"0```````````0`X0DE-!`H```````$``#A"24TG$```````"@`!````````
M``$X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8`
M``````$`,@````$`6@````8```````$`-0````$`+0````8```````$X0DE-
M`_@``````'```/____________________________\#Z`````#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z```.$))300(```````0````
M`0```D````)``````#A"24T$'@``````!``````X0DE-!!H``````SL````&
M``````````````!)```!!0````,`,``P`#$````!````````````````````
M``````$``````````````04```!)``````````````````````$`````````
M````````````````$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC
M`````0```````%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N
M9P``````````0G1O;6QO;F<```!)`````%)G:'1L;VYG```!!0````9S;&EC
M97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````!W-L:6-E241L
M;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%
M4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%
M4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q
M````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL
M;VYG````20````!29VAT;&]N9P```04````#=7)L5$585`````$```````!N
M=6QL5$585`````$```````!-<V=E5$585`````$```````9A;'1486=415A4
M`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4
M`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````
M!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX`
M```'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO
M<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG``````````IL969T3W5T
M<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/
M=71S971L;VYG```````X0DE-!!$```````$!`#A"24T$%```````!`````$X
M0DE-!`P`````"A`````!````@````"0```&````V````"?0`&``!_]C_X``0
M2D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_
MVP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4
M$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_`
M`!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!`0`````````#
M``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!
M`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R
M@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#
M!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3
M%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`+O^
M-_.RL5_2OLU]M$MR7/%5CJ]T?9MN[TG-5'K7U/Z_TCH1ZYC]=RKS2QEMM)?;
M6YK';=SJK6Y%FYU6_P#=^@G_`,<EH?U+IV/.K<>UW^>]C/\`T4A_6+_&`_ZP
M]+_8/1^G7@Y&QEI(]2PL80_TJ*<;?_.;/?8__!_X/_1VX"7!CX0*UX_[ML,B
M.*5D^#T/U3^O#1]4;^I=>M+[.G6G'=8`#9=+668[6L;M:_(?ZOI?];]>W_"/
M06?XUF5OHNS^CY.)TW*)]'-W!^YK='6-KV5M?L_PGI76?]<6-U+ZF]8P/J!6
MPTNLR_MPS\S'K&]]=9J?B,;^CW>KZ+?3LN]/]^W_`$2QL+)^J&=@X>!FV=8N
MSO;2S$JNK=0+715.,+OYFM^[Z.S?5_-H#'CEQ2`L61I^BKBD*'@'=_QB9N5;
M];>F48>7:RC)Q\:!3:]K'"W(M9O_`$3VM=O9^>NE^M/^,7!Z!G?LZK&?G9C0
MTVL:X5L9O&ZNLV;;'ON>US'^FRK\]<C]9:::/\871>FU$FK"_9N*S=J=K+=S
M=Q_>V.4>MV7?57_&([K/4,9U^)9<Z^EW`>RROTG>B]_Z/U\1S_YI_P#T/4KM
M1X(D0!%U`R`^7B59'%_>`OL]MTOZ[G-Z'F]5OZ9D46X-@J."T&RY[G^GZ7IL
M<RE_O==_HUEYG^,W/Z<ZIW4_J[DX>/<3L?98`\AOT]M+ZF>]O^C=:Q5?K']?
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M576FT[@-C-C-OTTS+&)B91%'C(\U\3(&B>CU>1E8^*SU+WBMO`GD_P!5H]SD
M'&ZI@93_`$Z;07GAK@6D_P!7>&[ED>I5:#U;.:;18XLPL7F0#'T?]?\`STG(
MQ,]_V6S%/3\PC=0X#:"1J)]M?A^[_44?`.M^:^WH4E2Z3EV9.+%VF10XU7#^
M4W\[^TKJ811I+__0]*=?DAQ`88!('L[?]N)?:,K_`$9_S/\`U*L[J60,?K^$
MY]YM9:&5#!KN<RQCG.>&YHQ*GM^W8[_H97KL?]DJQ_M-7_:I&S>HYU'5:^G5
M-K)RQ6_%<YKC#*WG]JFW:[_`XYQ_LW_=C)_/1OP53;^T97^C/^9_ZE41=D!Q
M<*B''D^GJ?\`P1!NZC97UZC!-K/1NJ);4P!UGJ#U'O.2-WJ44>FQGV:YM?I>
MKZ]-]E=EF'ZLNGY=UN;U2NRX7#&O:VK'#0U];3339#CN]_K6.L?6^Q*_!5)O
MM&5_HS_F?^I4SKLAPAU1(/(-<_\`HQ4?JYU3.ZDPVY#\=S356]]=3YLJN?O]
M;&MJ^E6VKV5_I_3R/69?ZE?^CSOVWUTT?:?5H`.-]L%8I?\`Z7T:<;<;O\+5
M_.V?SE=WZ1GZ+]"E?@JG?]?)B/3,>'I_^I$FW9#1#:B`.`*X'_GQ5\WJ-V/U
MO!P_48*,H/!K:`ZTO`<]KGLW;V8NQC_T[&>R[^=]BT:;JKZF74O;;5:T/KL8
M0YKFN&YCV/;[7,<U*_!5-8WY)!!K)!Y!K_\`4B0OR0(%9`'`%?\`ZD0LRVT=
M9Z=2Q[FUO9D/L:#[7;14UF_^JZWVJL.I=2/5_2W5'#^VG#;6&.W[?L?V]USK
MM^W>W(:^O^:]/T?^%2OP53=LR<EM;B6N8`#[A47$>>WU#N5-F8;\3('VBRZD
ML<++33MV`CW;=OIM=[?Y**WJ%K^N683[ZL=M(;Z6,YOZ7(#F&Q]];W.;^BK=
M^B_0L?L?CW^M_.5^G?W49>.X,>+*K`ZLN:01H358)'[KMS41(=D4Y%8I%^%M
M>YSJ:2<:OT]'-(UO^G]+:A7W7W8561:2^RK+:W&N<S8Y[9'YD#_6M*BNZVMF
M(UXIZGTYQ%)=H'L/;_,1GLRQ8S/ZP]K*L8S52S\Y_P";I_YG_F*3K_*_I_>0
MSJL?3U#J0IF)K<2UF^"6>X[6N:IX6=;;O]*Y^4!$EU.W;Y;F^DU$Z+59Z%F7
M<(LS'FV/!O\`@PM%,D19%7M^"0__T?551K^P_M>SZ?V[TO;ZGJ;/2EGJ?9/4
M_5_YST?M?V?W[_L_VG_`+YC224_522^54DE/U4DOE5))3]46>GL=ZD;(._=$
M;?SMT_FI5^GZ;?2CTX&S;&W;'MVQ^:OE=))3]5)+Y5224_522^54DE/TEUW]
MG[F>IO\`MFGI^C]..V[^3^[^?_HU0QOL/VIG[2^T;OS/M'T/[>[W[?\`P+_2
M+Y\24T?EZ_R_=6G=^JDE\JI*%<__V3A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(``W`"X`,`````$`.$))300&```````'``@`
M`0`!`0#_X1)(:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K
M970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_
M/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B/SX*/'@Z>&%P;65T82!X
M;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX87!T:STG6$U0('1O;VQK:70@
M,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\<F1F.E)$1B!X;6QN<SIR9&8]
M)VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G
M('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z9C<Y86$X-68M8SDS,"TQ,64Q
M+6(S,V0M838P9#1F8V0P9#`V)PH@('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA
M9&]B93ID;V-I9#IP:&]T;W-H;W`Z9C<Y86$X-6(M8SDS,"TQ,64Q+6(S,V0M
M838P9#1F8V0P9#`V/"]X87!-33I$;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I
M<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N
M9#TG=R<_/O_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#
M`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`$D!!0,!$0`"$0$#$0'_W0`$
M`"'_Q`#-```!!`,``P$``````````````0@)"@8'"P($!0,!`0``!P$!````
M```````````!`P0%!@<(`@D0```&`0,"`P,(!`H$#P````$"`P0%!@<`$0@2
M"2$Q$T$B%/!14Y06UA<*<:$R%6&!D;'!X?$C,R310M168D.#DS1DM$55=94F
M-D88$0`!`@0#`P<*`P0(!@,````!`@,`$00%(1(&,4$346%Q@9$4!_"AL2(R
M0E*"TF/!T17A8B-3\7+",T.C)!:2HK(T5"63LY3_V@`,`P$``A$#$0`_`+Z=
MT7<-J?:G+195NZ;5N<7;.$#F27072C'1T5D52&*=-5)0H&*8!`0$/#4VG`-0
MP","M/I&WFB6\9,ND&1"3Z(Y'ZO<Z[D)5E0#GYS-``44`-N3692[!U#X;%N0
M`&P?-X?H#;7=`T=I$!,],6[9OIVC_9[8Y-_W-J/#_P!]63'WG/K[(S!KSS[L
MS]FWD&',#N`O8]V@5TV?-,Y\@W+-PU4)UD<MW*-D.BL@<@[@<IA*(>(#J0K3
M.ADE2%V&UA0P(X#((ZBGS1.3?M5J`4F\5Y21@>(]CT>M'T\;]XGNB8GL+:P0
M/.'D5-/&3E)8\9DW(,SEJ"7%`X"9L[KN3U;9$'14Z>DY/0*(@(^(#XAXK-`Z
M+K65-NZ<I$`C:V@-'M:"".K?N.R/5-J_4],X'&KU4*(/OK+@Y<0YF&[\(O'=
MCSO8-^Y3#6/#>:8:OTKE1CB`)97J=;!5E4\JTE%VTC'ENK,8]=O'<--PD@];
MIRL=ZJJ0`Y2<MC>D=5%KS?XC>'9T@XU<+<ZMVR.JRC-BII>)RJ(EF20#D5(;
M"#C(JW=HG6@U(ARDK4)1=&TS,L$K3@,R0<01/UASS&$PFPIN&M61L"#2$&X?
M/I"&O\W+=,T'AGRSO-<GGU6L-.XU9RL\#9HMXM'2=>FH/&5GDXJ;C9!N=-PQ
M?Q;YLFN@LF8ITE2%,40$`'5YTXPU5Z@L5,ZV%M.5C*2DB84"XD$$;P092.!B
MV7IY=/9KL^TLI<13.J!&!!"%$$'=([XY7!>YUW(S&*4.?G,W<Q@*`!R:S-U"
M)AZ2^=S_`(?#^W7:G^S=(R$]+V__`/.SU[$=<<N?[EU'L-_K?_G<^KR$=9O#
M#:89X?Q2TL,E(S,\UQK16\Y+R[UQ)2TK,(U>+2DY*4D7:SAV_D7STIU5UE5%
M%%53"8QA$1$>'+@6S<*U3*`EDNKR@```9C(`#8`-@`E'5M$E::.E#BRISAIF
M2223E$R2<29\L;,U2\\5,&D(-(0;A\_GY:0@WTA"#_+J!Y]D-L0-=XGO:,.U
M?8L9X^C,"*YFO&5:?-7"+=/;ZC2ZW7647,!")_O1)O6['+RJKEV!S%33!J02
M$$`5`=]MF:!\.U:U9K:M=T[O3L.)00$9E*)$\)J2!AMV[1A&"ZOUH-+N4U.F
M@XSSJ"H35E`D98X$G'\8UQV,>[=R'[I%YY1N,O4S%M!I^(XC%QJ97<>1-D!Z
M1]<GEV)*+SMBL%CF!D_\O6D02(DW:`41.;80$-JSQ)T+:=%TUE%OJ'W7WU.Y
MU.%,I(R2RI2D2]HSF3%-H?5EQU._=.]LM-L,A&4(!VJS3F23,X<PC<'YB7-&
M6L#]LZ\7O"F2;QB>]!E+$D,VNN.;7/4JV,(V1LO5(MF%AK4C%RK1&02;`BN4
MJO2JB8Q#`(#J@\*;?07/6%-2W&D:?IN`Z2AQ*5H,DX$I4"#+:.?'F-9XA5E5
M0Z:?>HZEQE_BMC,A12H`JQDI)!$Y13<[6?.KGYFCN*\-,9W3FURWMU.LV?:&
M6U5:P<A\M34!8JY$2I)V:A9R'?6QRPE8>2CHM1%TW734160.<BA1*([[_P!9
MZ:TQ;])Z@K*?3E`V^BE7E4EAH*!*0$D'*"%`D$$&<]FR-/:7OE^K=16:F>O5
M6MI50G,DO.%*@#,@@JD00,0<#'3N`/;_``?SCOKC8=/EY?C'3&,>6O4(-(0:
M0@TA!I"#2$&D(-(0:0@TA!I"/__0O49O?EBL+Y=E#JJHDC<87Y^99`3@ND5I
M5)9P91$4S%4!5,$]R](@;J`-AWU6VU)7<:!`&*GD#M4!%+7*R458KD:6>Q)C
MC!"(B(B([B.XB;S'<1'S\PW'?7T%V2(,<<;-F[\/Z(Z_W;IA@@.W]PBA0*F4
M8_B7QX;G])`&Y%%0Q-4Q64]`?$AEE1,<P#N(B81'<=]<&:K<XFJ-1.`[:Y\_
MYBL/V\FR.N=.HX=@LB.2D:_^M/IW\\54/S7W"O#U$@L$<QL=4Z`I5YNN0)7$
MN5U*Y',HAM>UG=:?VNI6:89,4$$'-CBDZY(M5GH@+ATW71(J8P()=.Z_!'4%
MPJ7+I8*I]3E,VTEUO,22CULJD@G'*<R2!L!!D!,QJWQ3LU(PBAO%.RE#ZW"V
MYE$LQD5))EA,95`G:1*9,H@,['>2)W&'=7X8RT$\<-ALV54,;S"**AB)2$%D
MJ'E*5(LWB91Z5VY0F2K@4P"!542'#WB@(;.\1J1JLT3J%#J0<C'$',6R%@CG
M]6703&!Z*J7*75-F6V9%3N0\X6"DCSSZHMZ?F`>]3<."#>"XM\7WT<SY)7ZK
M_:FWY!>,FLP7#=&DUG+"$/"1;Y-S%N\@6E9FX4;B\271C62)5C(**.6YTM%^
M%WAW3ZE+MZO*";.TO*EL$CBK`F9D8\-,Q.1&8F4Y`B-M:^UF[8^';+81^HN)
MS*41/AI.R4\,RI&4\$C&6(BI-QEXL]U7N\6:^7/']PRCF$::X#[7Y+RUF:6C
M*Q&3<J07K6M1TO9)E0BTR[;AZH,8Y`Y&J`D.J""1TA-O*\7O16A&6*>I88I^
M+[#;;04J0D"2$CV0=ZB2=@F8U/;+7JC5SK[M.\ZZ$'UEK<(2"1LF3M.&`V;3
M(1KRA\P^Y)VM.0EDQ_'Y<RAC7(&);4>!O>'[?9WMQQS(.F"B"ZT9.4]])R54
MFX:98G340?,NA55HN1=HZ()DU=5=58-(ZUM;52Y0,O4=0C,V\E(0X)SQ"@`H
M%)F"%;""%`[(IZ:\:BTQ7J815NMU#*I*;4<R#*6!3,I((D9C<9I(VB^%D/G)
M7N;?86Y'<L(*.0K#N^\.\]P5PJY%%I%"JY`:5.S46XP#=90A'*\>6:!11@LH
M!5#L5T%3@`B(!S/1Z;>TYXFVFR.KSANO84A7Q-E25H4983E[4MA!$;SJ+XW>
MM"7&[(0$*<HW0I,_96$E"A/DGLWRE/;',PI$,-BNE/K_`+9VT5^'\#E3\9.6
M:,?`Y@.5/_'\Q`0#VAKL.I6&Z=YWX$$]@,<V,(XKS3>]2@.T@1U4N[9W%X7M
MB<0WF5V41&6;*=HDF>-\)4R34.E%2-R=1KEVK,SJ3-1!V:JTZ'8*O'9$!3%P
MH"#0%$1<E5)Q1H723FLK\FA4X44+:2X\L;0F<I)G@%K)`$]F*I'+(]2:LU$W
MIFTFJ2@*J5G(VD["J6T[\J1B9;<$S$YQS2\[<X.:O,7("DWE_.^7LFV:RS!$
MX>IL9^;;U]L_D7?2QA:9CNMJ-*]$@9PL5)NV8,2&.;I#8YM=>VW3>G;#3!J@
MMC##"$XJ(!5(`8K6H9E'E)5NV1S=77J\W=_B5E<\Z\I1D)D"<]B4)DD;<`!&
MQ4<)=TSCRQ9Y,2QASJP]$D]&2)<V-8SI2FR3<J97(.EYAFWCP;H_#AN)E5"E
MZ?/SVU2FXZ,NJE4BJRVOKV9"IE9)Y)3.,Y;O/$_N6J+<V*A-+7,HE/,$NI';
M(2[8Z7G.;*F8X#MR9HR9Q^CKK+YTG<%QX8I:X[@7M@O!;[D1K"P%>D:Y!QK2
M5=+R<3(V,CLO0DH"(("H8>D@FUQ_IJBM[VKK=171;8MJ*G^*7%!*,B"I1"E$
M@`$)ECMG*4S'2=\JJQO3M;54"5JK2QZF0%2LRY`$`3)(*ISQP$XI90O9\_,'
M\O6P6;,U^R17&LR;UP0Y&<H9TC@$G94A4.I2X.:NLC"E%-7<[=6/;*%$IBF3
M`VY=="N:\\++"2S04K"RG^13`C_C4$`\QF>6<:9;TCK^[`N5E2XD*Q_BOG_I
M!41T2'1$/?*K#G,OMN<C)+#&3<FV6EY;K$5!V-I/XLRY8'#=6'GT#/(>5B;#
M#2$9+,OB"HF_N5TFKH@EW,F!3$,.?62X:?U=:F[A14B'*):E)*7&DC%."@4D
M$'DF"1&(76CO.G+BJCJJE2*M"09MN*E)6P@B1'/,`\T7*.Q/W".3?-'M_P#-
M"DY?L5LRAESCO49F/Q[D%L@Z=9(MD9>,<W1Y58-T^CTTW-BNL'8:TJFS>=0R
M#HCE`JACJI^J?G_Q+TK9]/ZIT]44#2&:"K<!<09!"2AQ&94C@E"DJ&8;`09`
M#`;BT+J"Y7FP7AFL<6]5TZ2$J]]04A4DS&)4"DR.T@C?B:-_)J$Y95:[1-9Y
M@M<]1>1&5;;2,)#<@UKT-L9U23?/_A',8UORJDHV@G\DT==`H@""BZ:@A[P&
MVZ1LSUCJ*9Q^PJIE4A5(EC)ES`8@EO`J`(VF<I1I&Y-W9E]+5W#XJ`G`/9LV
M69D1FQD2#V1FO%C'//.ZM;F^X85;E-.,6#F$:9`=<<F^3CMF[I=*26KS>U*X
M\$B8+G12=F:E=#OT@H)-@ZM4UZJ],L*83J%^B0M4RCCEN>[-ESS_`'09<L3K
M92WUY+ZK,S4JE(++(7OG('+URGV1<0[R#:_5'\N=Q0K>4OMHTR2HEQ&@L@-<
M@!)*7<+<VH<K*V%E<3S/J2R<XWEXM07(N1]<%T^DX]0CK0F@33/^+-]>HN&:
M3_4J;X<LF4K2E)3E$I93A+"4;?UAQV?#VTMU><5/\`*SSS!0020J>,Y@SG%*
MOB[R,O/$G.U#Y#XR;0;K(6-%9^1IQ[&Q&3AH^?F*M.5IC-.8SU$R2"L">;^-
M014-Z*CA`A52F3ZBFZ%O5IIK[;:BTUBE"E>"0O*9$@%*BF>Z83(D8R.&,HTQ
M:[B_::YBX4H3WEO,4S$P"4D3EA.4YB>$P)X1D&:,X<PLM/D<Q9VR3GRW'NCQ
MTXBKQ>9N[&A)=945%UF]8>/%$:^DT0`!Z&L<!&Z"9.DA"D*`!+MMML-$#06R
MCI6^&!-"$IS"6'K#;/G7,G;MV3*RLNU6>]UM0^O.20I15(_U3LY<$X=$H?5V
MI>ZCRCX:<G</LF^5[Q;<$W"_U&G90Q%:K+-6*H/*G8YQI#2<Q7HB4=/$:[;8
M%L_,[9O&14%%542HKBJW.=,V,ZUT59=0V:N*J%I%R0TI;;J4I2O,E)(2H@#,
MDD2(,Y@X2(!%]TKJBYV:YTB15+50K<2E;:E$I*5$`E()(!$YB70<(ZH@>W7%
M8)WQU#"ZC"--9;SMCG"\>FYN4MM(NDCK1E<C2%>3LD"8B'J),_43(W;`<.GU
MUSI(]0"`&$P;:N5NM%==%E-.U_#&U1P2.O>>83,4]15-4PFX<3NW_P!'/#$I
MON-R@NSA7,9,$V!3[)GFYYPL\53`/VCHL6*"#8PF]@'5``V#?VZR]G1"`F3]
M>K/^ZD2\YF>P1:E7=1,TL>KSQL;'?<%I4Z];QV0*N]I8KG(D$U'O/W_#)'-T
M@4SU(K5I),T/'Q,1-P!?,=@W$*&NT75M(6Y1U`=`]TC*H]&)3/I(B>S=FU$!
MU&7GG#_(J5C9N/9R\._:2D7(MR.F,@Q73=,W;=4.I-9NX1,9-4A@]H"/C^C6
M'.-N,N*:=04N)P(.!!YQ%T2I*TA23-)CZ&O,>H-(0:0@TA'_T;LO,N8)7N(/
M*F=.M\.6'XXYND@6];X<4S,L:69<ABK_`/$GZR!TF\P';5VL#9=OME;`]JK9
M'^8F+;>%\.T71SDIW#_R*CCB;_S_`,H?.']FN^Q\(Y_1'(!V1V4^+$4:#XP\
M<8,Q5DS0^!\0Q1DW(E%P08['U>9B5<2`4HK$%'W]@`.K?;PUP#>UAV\7AV<P
MJI=/3-:H[#M:<ELMS9W,-CL2D13)_-?\V<<9%L^#^%N.;+&VF;Q%/SV3\SJ0
MSU%\QK%MDH@M<I=,>KMO41+98^%>2;M^WZ^MHF\:E.`'.8I-_P#@CIVKI6+E
MJ&K9*&ZA(;:F""I(.9:Y'W2<H!WY3NE&G?%2]4]2[16>G="EM$N.2,P%$22D
M\X&8GD!&^<0X=@S"D_FONK<66\0T56C,8663S3;'I4A41B8+&\.\EF;IR/DF
MF^M:D8P(;V+/";>.L_\`$VXM6[15[XADX\@,I'*IP@$=2<Q/,#&'Z#HUUVJ;
M6$":6EEQ1Y`@$CM5E'7&,]]*T6"U]V+FB[L3APLXBLEL*O&E<=?^6@*Q3:S!
MP*"!3E`2MPBF21R[>!NL3!OOOJ?X;,M,Z(T\&<$EDJ)'Q*6HJ/43+JY!$G7#
MJW=57DN$S#@'RA*0/,(=?VR^+W?%R;QI^V/;QR[8:5@.1R%:474+6L]53'Z(
MWY@UA6=B=R-=D)-L]1D5X]!@'JJE`56Y41#<G3JRZQO7AS1WCN^K:%#ET2TD
M@J94N2"5%("@")3)V88G?LNNG+9K>HMI=T_5J10<10DEU*/6$IF1(,\!COPE
MA&69;_+\][K/609_*V9:Q6<E9(M0QQK'=+;G_'<I8)DT3%,8.,,_?K3?J./@
M(B-0;I[^)4D2E\@#4B@\4?#BUTS5#;GU,T:)Y4)8<`2"23(9=Y)/28FU>@=:
MU[[E76-)<J52FHNH),@!B9\@`Z(FCBN)F=^WK^6VYJ8:Y$Q4/7\BN0R'-'B(
M.R,+.R9P>0K3CRJQA!EX)PZ8*+.P*HJ9,A^D`5`%-A$^M>+OELU5XMZ>N%J6
MI=))`F4E,U(2XHX&1PP&S=&9(M5?I_PXO-'<4A-3ZYD""`%J2D8B?/%)CBA%
M!.\I>-<()3&"9S_AR*Z4S)E,;]XY$KK38AE0,D4P^MX=0"4/;Y:Z)O;A:LUW
M<W)I73V()C2]J1Q+I;D;S4-CM6F+8WYP29G!M7!:OF6<?9PE?SQ,D;]!OA!G
M#R.,&2JWJ`'2=R5@D4O3YE*.^WB.M(>`K3?`U*Z`.,%,IGORR<([3Y^J-K>+
MJW.+8VYGA97#+=.:!/LAE_Y4ZDXFM'<(OLY>FL/(7RBX`LEBP^TERME5&=A<
MVFIP5DGX1)P`B,[&5:4<(D.F`JI-7;@P;;"(9#XVU-<QI6F:I5*%*Y5)2Z1,
M33E64@D>Z5`$\I`BS>%C-([J!Y;X27VZ<EN<O:S)!(YPDD<P,=%7YP$/`?G\
MA_3ON/CKD_9+DCH3;@1$'?>3[SE,[6M8IM0K5(9Y7Y&90B7\Y3*7)R*\34JI
M4V#LT6:[WATQ*:4=,'4JDJVCXYH*"K]1JXZG+8J/6?9'A_X?5.M7:FI>J2S:
M62`M8$U*61/(B>$Q@5*,\LQ)))C"=8ZQ:TPVPRVP';DZ"4I."4I!EF5+'$X`
M#$D'$2BF_9>]?WJ.;UW"@8CR?D9K-3P+#&XPXG8X"&F$6OK@!U64C5XF9R4F
MT9"Y*0[I:6,"1.DRJ@>>M_,^'?AYIVF[U7T+):1M<JG,PV3Q"BEN9V@!&.X8
MF-/NZTUG>WC3TM4X'%>XP@`RZ0"L;<3FYYQ%ERSPER<P7EYU7N7D-<83-UJ@
M(3(,ZWR#94+5>G<=9B.`AY"U2!9B;?H2[QO'")F[Y4CU),"`HF3<H:S6QW*S
MW*B0]8G&U6Y"BA/#3E0"F1(2))!$SM`E.8!,C&,76CNE'5EN[H6FM6D+.<S5
M(["K$XGGQBY5^4%B#(8%YF3_`$@!9++F,X@IO[S<1@Z;./1*("'H[`%@#;I'
MKW$>H`#I$>?_`!X<_P#9:>:GB*=P_P#$L?E&X/")`[C>'.5Y`[$D_C$,7YH>
MRC.]U2RQAE#*!3<&8=K9""<QP1*ZCIBW^D0O6<$P$]K$^P`7<3B.VXB(["\&
M6N'HIA>7VZEY73B$?V8P[Q-<SZI=3N0RVGS%7]J)I/R@S5`O'SF,]*79RXS)
MCQJL?K$0.@TI,DJV+T;@4HD4?*CN``)NKS'8-:[\=R3=-/HGZHIW#VK$SU@"
M,R\)$C]/O"MY>0.Q)/XQO+\V=8!C>WSB&#`P@%DY55!,Q0,H`&+%8TRG("8Q
M2_W9^@Q0VZO`!'P\=6[P-:"]4U[I]RB5YW&Q%?XK+EI^D;^*J3YD+,4ZNT%Q
MPJG+#N.\6<*7^%1LE`FKXZLUXKSH#&8SU7Q[7)N_2D'(ID,4ZD5-IULK1T4!
M*)VZYPW#??6_=>7=ZQZ1O5PI7<E4EL)0H;0I9#8/2,TQSRC4&DK:U==16NB?
M;S,%S,H'84H!60>8RD>:.@AWX:%2I+M#<L(IY5H(\;1Z/3)NF,21C-%M5)6N
M7ZGM81W74$D")PRD>Q5.V3^'!/I:+*(?X1S%'EKPRJ:A&O+&XAU7$<=6%&9.
M8%M1(4=^(GCO`.Z-^:[IV%Z2NJ%-)RH0DIP`"2%ID1R2V8;L-\<S[BW"A8^3
M7'6O&(50L]G;$<*8ATSJ$.65R!7F!B&31$JJA3@OL)2B!A#P#QUV#>G"U9KF
M[/V*9P]C:C'-ML27;G;6Y>T^@=JQ*.ROO\OEXZ^?TQ/GCL.-+YZS#&84Q[(V
MQT5)W++'"+K,2=3I_><XY34%N10"B"GP;,A#+KB&P^FF)0$#&+O=;/;5W6N;
MI@9-[5GD2-O6=@GRSW13550*9DN;5;`.4Q$IBS#>3N6%TF+?/S*Z$2>0*:RW
M.11,N45NDAB0T`S`4D5W+=J8A2HD,F@U1Z>H0W(0^Q;A=+?IVF:IF69NY?50
M.OUE':)\IVF<M\K"S2O5SBW%G">)Y>8=$2+PW#CCA5H]!I-0(S;HQ4TS2=FL
MDB@Z=J_LB8B,<^B6)!4..P%32#YO$?$<)=U/?*E94T]D'(A((\X43UGJB[IM
MU$@`*1,\YQ\THU7EC@12YB-<RF)7KFM3::1W#:#D7ZTE7I0>GU$VR;MR9>0B
MU%-]B*"HNEXAN4H>^%QMVL*IIQ*+D@.,["H"2ASR$@9<DIQ)?M3:DDTZB%[A
M/#RYX;=QDS=9L"9"7Q9D0'L=5'TR:)EXV4,)34Z>45!$DNWZS"FE'N%3%!V!
M!%$Z)@<%$>GW[Y?[2Q>*(5]#E54!,TD>^GX3S\F\;-\4-%5.4CA9=!#9.,]Q
M]`_'")H"B`["`[[AX"`[@("`>(#Y"`ZU<.2,DCRU&$&D(-(1_]*WQW6)]>L]
MMGG%*-"N5'IN,V68E@FS355<J2%BJ<A7F":2:`@L<3O)0@"!?'8?;Y:RC132
M7M7:;0H^KWQHGH2H*/F$6#5+A:TY>U)$U=V6!TE)`],<E;[&7#;_`.*60!_\
MBE-_^RZ[D+["O\=&_P!X1RCP7@9\)4N@P]QYSW[G+ZL?8MQRLYB?94(MO!A!
MM\GY49QY(9JW(S0C"),Y-N*;!-HF5+T@$I!3#I$!`1#6.ITOHY#JJD62@XQ,
M\W#;G.>TX8G?.+V;]J0M<']5K.#*67.L"6R0`(W1\#CIVZ.=7,*THQ6%>.&6
M;DI*OTAD;K,5V2K=&CU7ZY3+2%AR);$XJKM.KUA6/ZCLSA4O48A#CL`S;KJS
M3=@8SW&[,-R&"`H*7@,`EM!*B);,)1+MVGKY=G0FBMSSF8^T00C'E6J2?/YX
MZ&?9>[/M7[7^+;!+VV:BK_R<RRSCT\G7:(27"NUJ"8*F>1V-Z&=\@A(*P+-\
M?XA^^5316E7A4SF232;MDR<J>(6O'M9UK+3#:FK,P3PTGVB3M<7+#,=B0)A(
MWDDSZ!T;I%O3-,IQY8<N;H&=0V)`V(1,##>3AF.X``1!M^8U[->=;YF^8YY<
M6L?S.4X6[P$0GGG'],CUI>\5NS5*&;032_PE89)J2-CKLW6HQJF_38IKNV3M
MH=PHF=%<YT-D>$VO[92VU&F+U5)9<0L\%:S)"DJ)5PRHD!*DDF1)`(,AB(PC
MQ$TA6O5J[[:Z<NMK2.*A(]9)2`,P`]H$#UI8@X[#%;KAUW'><';;G;9&<?<B
MRN/&E@?(+WC&5SK#"P562EF2)$$7\E4+4P6-$3Q&8%1,[:?"/3HE*F=0Q"$*
M7;E_TEIS5S3#MSHTNE`]5Q"BE0!W!:3BF<S(S3/&0,YZYM&HKWIQ;R*"I+07
M[2%)!!(WY5#`[IX'JA[MA[]?>#Y0SD'BZLYY>U)W<)>-@6L9@[&U5J]@67F'
M:$43X6>C8.2N3415=E]]N]2$AMA`2CK'&O#+05F:>KGK;G2V"J;SBE)$AO25
M!!ZP8O3NN]7W-2*5JN*2L@`-H2E1ZP,PZC%P7\P`$S3.S/FFHHN9>S3CIM@.
MA*/E?CIJ7G%T,F4$LG)/'!R.7KMX[;1*SA9941.H<1$QA,;QT-X79*CQ`MU0
M0E"`7URP"1_#7(#<`"9`"-O:^*V=&UK8)6N329XDGUTXGEG*<XY_?;XQ[:Y3
MGAPR8.*C.&;N.4>!_6!W#R2#0$R9.K2IS+K';D3223`@B8QA```-Q$`WUU%J
MFJIT::U"KO`S=S>E(@_X:MG+ALZHT'8*9U5]LZ5,JQJFMH/\Q,\=T=!?OV]L
MVU]QKBG!EQ`BR=\@<!S\K>,9PS]VVCT+M$34<@PN^/DI)V9-G'2<^VC&+J/5
M7.F@9_')(JJ))K'63Y9\,M8T^D[VY^HDBUU20APC'(09H<D-H3-05ORJ)$R`
M#O[7>FG=16ML44OU&G45(!,LP(DI$]Q,@1/"8`,@9CF]E3Y(\-,SM'@(98XW
M9XQO+K*,W"B%DQS?JS*-S+,W)D15)&R1$'*9E$E`#J;NFYS$-UI'$!ZW_P#4
M:@MRT@,5=M>2)CU5H4-O.,#C+:#+9A'.I%QM%8%_QJ>M;5,;4+'1L/X$<N,Y
M9.+7<J[I/-3E-QDX[VWE]G*P53(&<L2URTQ58D$*<5W4G-X@TK$-@D,=PT!)
MN88(<5OBS.ECH&2W%;<H#K![UI'1>G;->+M3V*F0^W3NJ25`JDH(.7*'"H!1
M5+++&<HRJUZDU1>;I;;>[=WRTX^A)"3E]7,,TR@),I;=TL8EG_-6<$\YVK+.
M+^;6/:G8;YBUAB>,Q'DC[.QSJ:=8VE*O:+98X6P3+)DFL[9U.QL[>HC\9T"V
M:O&1BKJ)BY;@;!O!/4EM9H:W3U4^AJN+Y=;*B`%A:4I(!/OI*09;2")`R,LL
M\4K'7.UE)>J=I3E+P0VN0F4%)4H$R]TSVRD"#.4Q$#?:][MN7NUF^S$\Q7BG
M$^2?QBCZPTEE<A,9I*5AEZBM-*Q@Q,W7I2,D`B7/[^6%XR.)DEU$T5"B0R8B
M;9FM-"V_6B:!-96OL&G4J7#((.<`&84%#-ZH(5(&4P09Q@FF-65>EUU2J6E9
M<#P3//.8RSE(B1EB9C?AB)"&]<W,_P#*/FWR"LG([D)2I!C?KO$UX&\?`4"<
MK%=852+C4X^L-:_&O"/7BT.G'HAZ;E9PY5<F$QS+',;?5VTY:[+IVU-6JTO@
MTS:E8J6%**B9JS$2QGND)#<(H+U7W.]7!=RN#)#[@&Q)2,H$A('&7/CTF+I'
MY2VL24'PCY#R$G$2L4ZE.4;]L49)H[9D<H1F*L;G(+9)V@EU@DI(F`YR[@.X
M`.PAKGKQR>;<U%:4H<"@FB!P(.UQSDZ(W)X4-*;LMQ4I!!-41B);&T?G$'/Y
MH?C7EFB]PN?Y%251FEL/9PHN-AJ][:Q[A:M(V2DU"*HD_3Y*62(=LPL38U?1
M>D;K"0RK5ZF9/K`%`)LCP9N]#4Z4;M**A(KZ9US,@D!65:RL+`G,CUI3V`[=
MHC"/$ZVU=/J%RXJ:/='VT952.7,E(203LF,LY;QB-AB&#BKS>YC\17%JA^)^
M;;_BY7*)XAC986G),9(MG>QQG:$(H2(DHR92"9;#)K)-W#5--X4JQB%4V';6
MP+YIS3]]33N7V@:>X`5E*@1E!Q5B"#+`3!PPC#K7>KQ:.,FU5CC1=D%!,O6(
MG+`@XB9D1%L'\STTR!"\).VYB6S.K/>;ZB]D92]3KM-[-S,U:J/BBGU^P3LV
M[20744D)6:MSA4QS&+UG.?I`0#W='^#AI7-1:NKF4H:IB`$)&`"5NK*0!N`2
M@"6W9&U?$L/MV73E(XI:WYDK)Q)4E"023RDJ)YXBA_+/4:<)W7<8RTO`2T>A
M7\6YJDTG,C$R+5(J[FCO(("IK*HI(D6.E,G#WQ$!*)@`-Q#6;^+]0W_LBM0A
MQ)*GFA@1L"PK\(Q7PW97_NJE6I!`2TX=G[I'XQ<#_,+33F+[1_*=DR:NWKVS
MEQ16FS9BV6=N%%)#,M"<*%(BW*=40^&9'ZA`!`"[[[!OK0_A6VES75D)4`$%
MQ6/,TO\`$QMSQ!<+>D[H`)YLB?\`,3'.][?U'LRO.[A>1]6K*V:!RLX_*.%_
MW+))$120RO5%CJG5.T$B21`3W,8?`I=Q'8`W#JS5%2R--:@ROHS=Q>]X;VE#
MEZN?9'/EAIW?URS!3:@.]-;CN<'E^4=/7)O-*5QYS"QCQ?1Q'(3D1?VL3\9?
MTYMVV=1CV=.\^#4CJZ%=<LY>'8I,%E':XR2"A$VKLPIE!L`K\<46G45E@K+R
M:X)<:)DB0,PF4P59@03,`>J09IVS,NF*F\JI[Q2VSNDT.`37,X$D@2&4@@2,
MS/<<)"9;AR\G9C,'(>OXDKZHJHP*\75V27B9L%@L7PKN8D%@#_49MUD$U1V#
MH*U/_#ODFFVD6RQO7%X2*P5GERIF$CTD?UH\7!:JBK33I5(#`=)E/>?V2AU&
M:LG07$G$M7H&/FS0;0[8&8P!'"1%"M46X%_>]OET"B`.7CIZJ(D(80(JX.(^
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M770WB6\T^9E#TY>M3)4P@9=82@`BM'.UTT.HWO"FY*4VP)``6+2=<]2U;UFJ
MYIQ5('W5@^LGKQ/2,-L5MR90XVBK;Y!/D(.PGKASO$C(JV1L)5EX^<"XF:V*
MU1EU3FZE55H4J16#A4P[&.HYAEVQSF']I03>W?5AU'0BANKZ4B3;GKI^;:.I
M4XK:!XO4R"H^L,#U?LAS&K%%;!I"#2$?_].]U*9(H,>Y=1<K8&"3AN;TG31=
M%PITF$I3=!R_#*)G\!#YPU6-T%:L)6VPK*=A$25/L":5+'1'Q@R3B;?<9J"\
M0_\`#UO/P_ZCN&IOZ?<Y_P!TOM_;'GC4WQIGY<T*.2,2C_WS!?\`IZW^PZ&W
MW/>TOM_;#C4PQS)CW2Y;QL0`*6TQY2E*!2E*B]`I2@&Q2@`-=@``]FO/Z77S
M_P"V/:/SB/>&/Y@CR_%W''^];#_FGW^RZ?I=?_XQ[1^<1[PQ_-$(.7,<#_\`
M:F`_\D]_I:@&AM=?A_IE=H_.'>6!_BB-?6D_&6\K%<W6OXPN#@H]95[52(JP
M+%.`&`#D5EX1X<INDP@`[[@`ZJF&K[3"5.M]L?N+*?0H>B*9U-N?,WFFEG]Y
M(/I!CW:Q*\=:24J=-C<>U(A0V*2LU%A`D*'CX%+%0[4"AXC_`"Z\O4]ZJ#F?
M4\X?WE$^DQ[;[@S_`'*&T_U4@>@1EZV5<9.""DO9HQ9,1`PIJMW:A!$/$!$I
MF@@(@.J86RX#$4Z^T?G.)I?IU8<0$<_EC'KER5BDAR*$G(0AR&`Y#$8K%,4Q
M=MC%,#(!*8/9MXZBJWW(S!8601R_MY-W3$./3;EIP\N2/<_%O'/^]4?\W^$]
M'^/;X74/TNX8?Z=7F_.(]X8WN",/MLQQYOR*3:],,?75N@)110ME48V-%$2G
M%0OI)3$.]33Z3F$0V`-C"(^W50Q37FEFJF+S9.W*HIGV$1)=-#42#Z&UC]X`
M^D0E7E^.]'3%*DQ^/Z<D/4`IU:ILJ^00/OU;EB8=F4>H1\?GU%^GO53C4EUS
M^LHJ]),&C0,8,H;0/W4@>@",O/EG&R@'34M$:=,Y1(<AT7AR&(8-C$,4S02F
M*8!V$-MA#5.+97@@]W5S;/SB=WBG_F"4:Q1BN)[>:-8V]+P^A83*F7//(X[K
MZ4R98XE$ZHRA*^5\94YB`(F]3<1*`_-JKRZ@X89+M1PI>SG5+LS2]$4O"M86
M7`PSQ.7()]LHV*;)>*E!`5)V$.)4RI%ZV2YNDA-RD3`3,AV3)_JAY`&J7]/N
M0V4Z]^_EV[]\5)?II&2TR\I1^J.5<8MR]"%DBT""/4)46SI,HF$`#J$I&A0W
MV``U`VRX*,U,*)Z1^?EC#O%.-C@E'IR^0L03[!Q%3TK79N,=EZ'4=+QAY)@Y
M)XAT.&;Q@NW6+XCX&*(:]-T%T96'6FG$N#>#(^8]D04]2K24+4DI.XXC&,'K
M;3BO378R-0J6)JK(&$AC/JW0(2#>F,F.Z8BZC(%LN(D']D>KP'RU4O(OSZ0A
MYVH6GD4X5#SJB2VW;625,LM(5RA('H$;#5RCBYQT_$V*)<=&_1Z[1RKT[[;B
M4#LS=.^J5-MN0V,*!Z1^<3R_3JVK$>*>3L5H']1"?AD5-A+ZB+-PF?8?,.M-
MD!MA]NBK=<E"2F%$=,_-.'&IA[Z1T1^BV5\9JIF(O98Y9/;J,F=L\6*;I]X`
M]/X,_6;Y@`!'?R\=03;+@#A3JGT@;>N(FHIY?W@EVPUZR\KG4=,'1I^$74W%
MMUQ*G+RLFVK[ER"9_=<-6",)*J(%/L(D]54A_+J*4=P#(&--)<;SU5U"'"-@
M!5CSG,#NW"*!=>0H\.DFGE.$_,>F-W4C/E'ML:C*3S-S2IMIUH*1D\W%=9N"
M_2*AHV4:('2=,U_1+U"'I'W*`'3`.D1M-79:NF<*&5!YG;-)VRY4G?V\T535
M6TXD+6G*H<N/8?Z(8!@ILH?E+9\F7INXAH8K^]6"+DY1JX*W</95\JRC44!!
M)0_JA'R)SDW`-BI^P0V',KM,:?8H*,A;A2VD@2G(#$GK&,HM5+_WRWG,$@J.
M,I&9D)<^^<?+S'&/,T\H4EI@K]MC-"3A8(MB,BX+'I5:*;$=R:C9;I%1,TB\
M.Z!(P$`/46*/CXZ]VM8M=@4&P#7%*E99XYS[,QS"6'-+;"I!J*T9@0S,">Z0
M$_.8>/E/E+5,-Q\'%4:D.K="L639-TO$G-"5VNQB2@,VC%-R>-=>H\`J8;)@
MF5-,HD$QQ$VVL8M^G:BZ...5=4&WE$R!]92CMG*8],YSPBX5%>BG"4MM9DRZ
M`.:,'Y*QU0Y`\;V>9ZRWVD:VU+-Q[A9,A)%O'D?ECK/7Y`4^L!*Q5*=;;<2@
MHWZB"!3B)JNPKJ;+>UVNH/\`#7ZI`V$RFE0Z=G7CB(E5H;JZ+O+8Q&/GQ'EO
MCY/&UZ.3>(&0J-(B9RK7VEQKK/U1ZS%06B2V&%,`CN.S21>&*0/,H)!MX;:F
MWQ'<-34-6@2"U-J/4K*KM`V\\0HSQK>XTHSE,#TCS^:,!X!9"@ZU'9*A+#*(
MQC8[VN2L>9P"QBJN%D95G(=())*"`@1LVW\MP_1JLUC1//KH7F6RI4E`]&!'
MI.$2;2\A"7DK,MA],.7R)RM&NR1XVAX]D[T1#I!Q,.)$:_$',(;F*Q$T;)/G
MA2>0G,DB41#W>H/>U8Z'39J$YZRM2TK<D#,KKQ`':8JWKAD5E:9*QRSE^!C)
M<:<F(:W)+H7*MR./)1ND"NSU89:(>!N4IR-))LT;KE7(([]"J!-R^(&,.X!3
MU^GW:90-*^E].S`95#I!/XQ,9K4.#^(@MJEOQ';&UPRUCD2&/]J6'042E$?2
M>[`)P.)0_P"B^8E(/A_!JW_I=?\`^,>T?G%3QVMN<2C_U+N=EI>6W\[(NX97
M&A8Q=<#LPE&SXS_T@3(7_-&3@')#*]11\CF\-7NGJ[8VRA#B:C/+&4I?]44B
MVZDJ)249><?L,?#_``_S=]/B3ZK(?=C4_OUI^&I[4_5'CA57V_+Y83\/\W?3
MXD^JR'W8T[]:?AJ>U/U0X55]OR^6#\/\W?3XD^JR'W8T[]:?AJ>U/U0X55]O
MR^6%_#_-WT^)/JLA]V-._6GX:GM3]4.%5?;\OEA/P_S=]/B3ZK(?=C3OUI^&
MI[4_5#A57V_+Y87\/\W?3XD^JR'W8T[]:?AJ>U/U0X55]OR^6$_#_-WT^)/J
MLA]V-._6GX:GM3]4.%5?;\OEA?P_S=]/B3ZK(?=C3OUI^&I[4_5#A57V_+Y8
M/P_S=]/B3ZK(?=C3OUI^&I[4_5#A57V_+Y83\/\`-WT^)/JLA]V-._6GX:GM
M3]4.%5?;\OEA?P_S=]/B3ZK(?=C3OUI^&I[4_5#A57V_+Y8/P_S=]/B3ZK(?
M=C3OUI^&I[4_5#A57V_+Y8/P_P`W?3XD^JR'W8T[]:?AJ>U/U0X55]OR^6$_
M#_-WT^)/JLA]V-._6GX:GM3]4.%5?;\OEA?P_P`W?3XD^JR'W8T[]:?AJ>U/
MU0X55]OR^6#\/\W?3XD^JR'W8T[]:?AJ>U/U0X55]OR^6#\/\W?3XD^JR'W8
MT[]:?AJ>U/U0X55]OR^6$_#_`#=]/B3ZK(?=C3OUI^&I[4_5#A57V_+Y8/P_
MS=]/B3ZK(?=C3OUI^&I[4_5#A57V_+Y8/P_S=]/B3ZK(?=C3OUI^&I[4_5#A
M57V_+Y8!H&;R@)BK8E,8`$2@#:0#<0#P#?[,;!N(;:=^M$Q--3VCZH<*K^WY
M=0_*&?6_/^9:+.+U^PX.L!'R"ITTUHVA.)J,>E`_I@M&RT/&O8]\BIMN!DE3
M#L8`$`\M9)36>TU;*7V;JC(1/UG`".D$@X<XZ(M[E74LJ4E5*K-S()':`0>B
M'`8U3SWD*!^T#JEU:AH*G*5BPN\2>,FGB/0!Q=#$MX=V[8H`.Q2@Y!%0X[B!
M>G8PV>M59J%[@IJG'CO*%9D@\DR0#RS$Q%4SWMY&<M)2.0B1[)8=<:IQCF2]
MY1R),8TC8BE0\["H3*BRTPR2(R<G@I!&/>-VQF44[<"L!E3*%`R90],@B(@;
MPU<:^V45OH6JYQ3RV5%(D#CZPF#M`EUQ)8J:AYY;`RA29[=F$A+IC\'&;+NQ
MS,7"DE$TJ.GS3B%?),N&2(01W;UHF[C5`4+&"^!%_P#$)$3W1WZE"@.P>.B;
M71*M8NK:G2SD*LH/K2!(._=(SQB'>7DU/=BE(43*>$OSCW>11\YUNO.ZDOC^
M*M<=<XE6,&<I,"YEV\>NLMT*,W!$H=!^T?@DF4Z)A3!,XG]T_44P!YLIM#[P
MJ$5:FE-*!RN*`)'+B92Y<<(C6=[0@M\`*2H2F!.7)S]$96E6I'"7!JT0]Q(5
ME.2\%-%6C%5">JR?W5^#!A'&$#"!GC5LZ(HL4-Q(H4X>/3N-*7V[KJZG=I9E
ME*TX\H0)D]!E(<L3,AIK8XET^N0>TG`",<X2-S0^`,O61Z`I,%G\^<IA$2E,
MA"5%!5TJ7<`#H+\4)=_G)[-MM3]5*#MYM;"3-8"?.O9YO/'BVIRTM0M7LF?F
M&V-(\)ZW>)UQD56G#52`V;UI&04M"3E4F[A29.V*Q^'C9'8XE;']3?H'80V$
M?9=M4U%(PFA%27)G,1DV^[.<R,,8IK8EY2GBT$C`;>OIC;^5<H9OQ'+'CYO$
M3F=CS&+\'9*?45;)!/2F\0$'$?%*KLE1'<#).4T5-_(HAL(VR@H+1<6@IJY9
M5`8I6YE4.TR/2F8BH?JJNG4$KIRH<H3,?TQEN([%GG+;=Q((8WCJ/#HI=:,I
MD"NGKY9%;U`(5"/C5(E67<EV*)A6^'*AL&WJ"80#4BY,V:VR;57*><.YM6:0
MYS,)ZISZH]TSM74@D4X0GE4)3ZI3C=P8_P`V>F<HN<4=8J)"4?A9#IZ"D6*?
M?_VUOU;F+MX;;;ZM7?;1FS9*G9RCZXJN'5<C7EU1_]6Z;SCS3D3CIQ$Y!YQQ
M-34K]D3&.-)ZUU:M.6,E*,%7S!-/UIB6BX4Z4S*PE68J*RKYJS,5VY:,E$D1
M!0Y1TB*1,@1@O$.LYO?Q5=S!;.=S7EWC#(^/F4U74H/#6(J+2%GTXI&RD=;\
M?V7'K9&>-6P8`NW28RCN76%-8IE'/K)#UHBJ0)&61APN9LZ8WP!!U.S92F'<
M!7KADW'N(XN91A9B7CVETRG9&E0I*,\XB6;U.NPLI9I%LR/)//18-EW*0+*I
M@<!TB`!.R/+(F<L;8MN>&\>W"9=-[IGVYRM$Q=7HV'EIJ0GYJ!J4W>+"Y73B
MF;LL/7Z_6:^NX>R+P46383(IG4!19$AT`)SCW<TYFQSQ[Q?<,R9:L):OC^CQ
MZ,A/R_P,C*N0%X^:1,5&1</#M'TQ.3DY-2#=BP8M$%W;UZY2013.HH4HH`$F
M0$8[A#.L?G*-FY%EC+.&,#P;IB@M&9OQ39<72DBA)ME7;*0A$)]`$9=H9%(0
M7!%4R[)002<IHJCT:0(EOC0W,KG%"\0+-QKK4CBS*F27/(/+RN.@-CC'&0[T
MI7XB-HESNLO),T*/4;.,];4TZP06E?*9%^^CP?/40.C'.-D12G-/&'E5*R-+
MC5Z];6#"P1+*R0T=-M8RUUZ8J=GCVTFU2>),Y^L6!FPG:_,-R*@5PS>().6Z
MH&34(4P"`(\PT3(?/[!E!N>0:2R@LU93=X<,DGFR>PGA7(&5:CAYR>'0L1XF
M[V2J0[V/&S,:^[1?.X6,&2F631=)9PT234(8R/679B(=C1+U3LGTJJ9&Q]8X
MJWT6]5Z(M=1M,&Z(]A[#7)YBA)1$O'.D_=6:/F3@BA1'80`VP@`[AI'G9#.\
MF]Q;COC7*^1L#HLLT91S9B=G5I>_8NPK@K*&5+57ZQ;ZXC:8JX.B5:MNHHU8
M_=;E,AW)70B9X<&B15'7]R"(Y3('=&M%>[SPK4J$3E"`L65;IA)=*O&MV?*9
M@S+$_A7$Z]E49(M([+%^;U4L92Y>)<22"4RT6`[FOJJE+*$9COLB.4[-\2;)
MJ)K)D51.15)8A5$E4SE,15-0H'(HF<HF*<AR"`@(>8>(:1YAGU:YO8FO&7YO
M$5!J><+[]ELARF)+=E2GX7O4YA"JY-@1!&Q4Z9R<WC`A"O:T_$6<HZ0]:-C'
MQ3-G3E%<IDP1ZR\IAXVD>8-(0:0ACK;.F1''<EEN-*;V)/B2)X10>;G,>2(2
M--H9)F\[3U%;.'$^"WK)1BM5@S@DR%/I.H!U>K<NVD1EZL^>-^\@<_8JXO8C
MM>=,VV0:?B^CGKH6FS#&R4JE#)6>U0E.BW;IG$-'KT&(3EA;%<+`F*;5`QEE
M1(DF<Y4`"<!#7H'N7\;YF\XYJ,A$YXI$'F6T1M*PUEW(_'S+5#PKE.USJ;E>
MM0=2R/9:NPB"NK>@U,>&,_!BC,%,3X(Z_63J1'*8D%]H#^H?,!TCS#%&7<+P
M?8[I+U7'%0Y!YBA:U?5L86C*N'\`Y,R%AZ`O+&82@)F#4R!!0:\7/EK$PH*$
MN[APDF,0HDJ#Q9'TE.ER1ZRG?*'U"&_R_3X?KU"//5`/EX?J]FW]6DL)"$0U
MV)\/'[FRXG'H?"U^2M1Y9RMMLB-<OJ!RR+G<0]Y.-=OUA'_AMMOT[/83^LZ4
M#2<7DMY0.539D!UR';&.K/=+EG.""KS*V^GMC8G/'%4JQGH/.=7(L+51&.C+
M&\8"8%HN48*%&OSH+(#ZA$7:/0W!4!Z4U44O'J4#5%I"XMK9=M%01FF5)!W@
M^TGJ.,MX)YXG71A04W4M]<N7<8RO&'<!K`5QJQRG#3B5E8MR(K2M<9LWK&<%
M$@%!V9JL]8GCGSCIW4('4@)Q$2F*4>@M-7Z,?XQ7;G4<%6Y1(*>;`&8Y-_XS
M&+L@H"7DG.!NWPV7/G(6T<F+!`T>G0,@RK@2J*<'7P,5Q,6*<=`+1L^DP0$6
MZ)D$U3%11*90B)3G.<YM_<OUGLM/86G:NJ>!?RXJ]U*1B9=/*<3NE%%5U;M8
MI#3:2&YR`VS/*>C=#O\`+J++C;Q#;X\2<HGLEC9!6#G2/L#V6GU%)"W/4_(Y
MVC9D==%,PA[H"B!O$?'&K85WW4JJX@]W;.?H"<$#I)D>TQ<'P**W!H'UR`#T
MG%7XCLCZW`&GK0>))6T.4S)JW2QN%VO43I$\5!IA%ME`W\>DT@#O8/F#<//4
MO6-2';DW3I,^$V`>DF9\TH]6IHHIU+(Q4?,,(?6(?+_1\VL2BYPNF_9"#2$?
M_]:]3F/+='P;CV<R;DA:=:TBO&CB6!_7J?:[V^CFDM)-(=-^O6Z3"V&R.HQL
MZ?)BZ509K%;(=2RO2B0YRHB)G9$0?#RU8Q:\^9^`[?LE8+)PSR5BB^Y+Y*5N
M*JEJB^.^'^1!K15!H,UA::L$7%PD)=<NQTI.C:JM`B:/3-&I2*R#=T=05$>U
M>P,VT>CGB3?F'@!GRDXP9NP&Y>#%OLCT&9BJM/%-T*U:^LB%FL=W!JITJ"F[
MJ%YC8^22-L.RC4/#2/`VB(YNV_=[SSKR:/.[+=3DZF7#>(HSB9C*HSC!5D>,
MS,@,-*<X;Y'LW0"8J3C+,`QI4>[+L8S2J.]@*#E0#(]KD/5'3$@?-'_\VON.
ME\J?+546^"L@(L:1;'01]M=%8+S#M-:#E0DZ7'OYBHNX.99(O6LWNV3BGC9%
MP+A(Y"&TCRF<Q*&Y]M'-62<G5K.-*LUVL6>L6X3R9%4;`/+.RU.1J,QR'QT^
MI4%8E5YU)]%PS*XVO%T[(.*Y*6F-;-XVQKLP=D3*N+G=!0&!$8]W(+K#8PR]
MVV,H7\SV&P[CSEU;9[(M\"-GI&OT1>3XLY]I=,D[.:":/@BXV4L%L!@F[=)`
MW3<."$,<GJ;BB*/?Z(D_@)R*M$#"V6"=?'0EABH^;AWWH.6P/(N59HOH]T#9
MVBW=MP7:KD.!%"$4*`[&`!W#2/$5I,*PG'_CY8.1^)^8G)#F;QKS.3E%R+R:
M1&L9:SS1\8YTH^7,J6;(%`RGB5O08QW4[.YFZI.M(^4C62KB793+!=!=`H"C
MUQB:23ED!LB?WC)B7%N#,`8FQ1A-K-LL34^F1;3'[2R.9]U.HUI\4\Q'EE3V
ME)"QIO.B2$3I/DTG*`CZ:A"&)TA")9G,SVPT?B#`J_\`[@[J%Y>0TNR=S>8.
M-M.9S$E$+1[29@*-Q>H3AB$(^5;HI3$:PEK8_3,JD=0I')E""('`P:1$GU4@
M1'97JQ-1WY=7(,$E2[(PL]^QQG,).JH5>4:6I>:R]R/NQ)!5S7FD0,N9TY+:
M16.(-1,9O[_@3WM1WQ&8SSGA%C&+9!&QD='%'<K"/9LB[;CN#5NF@`@(@`B`
M@GX;@`ZA'DXDQ!E2LS8XQ]SRJ;/@S?K!DJI\J,TW(O,SBS]A;ZC$8AMB54L#
MV=Y<0DM8:U$&PO(N[15F4;9HI^<(VXK2B3QBB5^4[A='K:DYMT2^TG/.*\C9
M.S#AZEV8T]?<"/*?&Y8C6T/.)QU3E[Y7BVRMPBMC<QJ-=DIMQ7%4GB[1FZ<+
MLD5T1<%2%5,#(\R(`,;@TB$&D(C&I<7,.^\%GNPK1LLC`P_;_P"/5:82JD0\
M2AGTG*9USG-R+-O-G3!B\D(]NT;F403.*B1%P$P`!@W1[G_#2)XS,?MW<X'[
M9<*IG'ZD#)V9AD///$6G3<)%1"LXJ^KLERJPZXL:;R/1:O#GB`@V3@7AQ)T)
MM@.8XE(!C`B",%8\_HCVNYO"O[%CGBS5HJ%D9<9GN"\*`<DBFC]P,7&U_-$+
M;GLN[-',G?P$9'-ZX)EEU@2;I%'WCEW`!1%!Q,SNB0^Q,9"3K\[&Q,@,3*2$
M/)L8R4*`F&,D';%=NR?@4`W$6;@Y5``/:72/(VQ#AVUN4&#,`\9>./"O+JDS
MA'DWBB*@L'W'"MII%X1L,QDE*86C'EMJ;UG6G,1>ZAD>8=C.MK#&N'4<JWD1
M5<+I'*L!$14#.>Z)6+WE^EXXM.*J;9E)\L[F6VOZ51TX>J66PL5IV-K<M;7H
M3\I!Q;Z-J<:G"PC@P/9-5JU.L!42J"J<A#(\QM#Q_H]GE\X_QZ;<(0P;G5A9
MS=*BQR37VAW,]1VZZ,TW03`ZSZIJF%PLN4H`)U#P+H3+``>2"RQA_9`-9?I&
MZ)I*A="\N3+IFF>P+Y/F&'3*+5=*8N-I>0/63MZ(Q'BER8J]JJK;"^6G3`'J
M#((."D)\458FT0AD_AT8&44>=2`2+5$?13]78CI$"EW]4H@>JU%8JBGJ%72V
MI5EGF4$X%"MN9,I&1VF6P\T>*&L;<;[O42GL$_0>B,SMO;^Q9.2:LC6Y^R5%
MNX5,J>);_"R\:@"AQ.8D>+XI7S=/I,(`"BZP%#;8-@VU24VLKBRVEM]A#JA[
MQF#URF)\X`W\L3'+2PLDI64@[MW5&PZ=AS!'%2&?7>1?%2?-VRB2UNM3ENYE
M3%.4PFCH!FW01*DN[_9!)JB9RL'NF,8OAJCJ;G=]1.HI$(]4GV$B0PWJ,S.7
M*3+S1-;IJ2@3Q"<1[QV^7GB.?(%RM_,7-L+`U]HY:0@.3QE98*E%0D'7RJE5
MEK),%(8R)7:R!/67'J$``J3<AC&`HFS:CI:73-K<=?4"Z<5G9F5+U4IZ-@W[
M5<LK0\XY<:A"4S"-W,.7\^H1-14JS&4RLP54A4O1BJ]%,HED00#K%)F@1'U5
M1#]M=P)144-YF4,(CXCK5M14.53[M2\9N+42>O\``;!S1D;:`VA*$[`)1D6I
M,>X-(0:0C__7O\:0A-O9_+M[?U!I"&[\C*1R,OM6;0''7-E*P5+2*,S$V:W6
MK$KK*\NQC)9B1JSFJ$T)D"C1<+<:ZXZUVJLDE+QJAS`"S0X%TB((&T1DG'K!
ME)XT84QM@C':;_[(XSK+2O1SV8<_'3LXZ*=5[.6FR2'0F,G:+=/NW4I)NNDH
MN7[M940`3;:0)F9QN00WTB$'CI"%TA"`&W]7\VD(3;Y_9L.W]'LWTA"[>/G\
MOTZ0A0^7]OMTA">SV_H_HTA"_+?2$>/D&^W^GS\OZ](1A-*QK0\=*W%>CU:(
MK3C(5UF,C7AQ&-_2<VF\SS>/9RMGFG!C'6?2CIC$M6_6<1!-LV22(!4TR%!"
M9C.-(0:0A`^7R^;2$*.D(3Y]_+2$'RVTA!^OV#_3Y[>&D(/D`_+?^O2$`:0A
M#D(H0R:A"G(<IB'(<H&(8I@$IBF*.X&*8H["`^8#I,B1!D1#IB+?D/P=D%9&
M0N.%VS=9L\44=R%#,JDT4:+&ZE%E:TNN8K51LH?Q!FH8@I#[J0G*)4R9_9=6
M("&Z6Z$A21(.8XC=GWS'Q;]^,R;)5VPE1<IQ@=H_*&D(7WDOC`@5W]]Y0JR+
M;^X2B9%.8*BW`GN@5DA)(+)I([%V+Z.Q!*'@.VVLD51V&XDO\%ATGWA*?7+\
M<>:+?Q:QGU`IQ(&XS_'#LG'T8/$_(SD!,MG3]C<9DAS%(:S7AS)-H9@W/MUG
M2=RW@=(`+_A,TU3_`#%';7AVXV2S,J0VII,O=;`S$]`_&75$4L5=4H&2C/>J
M<O+FB6GC_P`=ZQ@F!52:*%F;;+))!8K.L@":CCH$%`C8Q(1,9C#H*^($ZA.L
M<.M01V(4FN+S>JB[NC-ZE,GV4CTGE/HW1?Z2C;I42&+F\_D-PAPP?Q^7G_5J
MS15PND(-(0:0C__0O\:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"
M#2$&D(-(0:0@TA!I"#2$&D(-(0:0A!\A_0/\VD(3VA\OGU!'LPWGHCRU&$&D
,(-(0:0@TA!I"/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
